http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201790546-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4418 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201790546-A1 |
| titleOfInvention | PYRIDON DERIVATIVES AS KINASE INHIBITORS REARANGED DURING TRANSFECTION (RET) |
| abstract | The present invention relates to new compounds that are inhibitors of kinase rearranged during transfection (RET), to pharmaceutical compositions containing them, to methods for their preparation and to their use in therapy, individually or in combination, for the normalization of gastrointestinal sensitivity , motility and / or secretion and / or in disorders or diseases of the abdominal organs and / or for the treatment of diseases associated with RET dysfunction or when the modulation of RET activity may be therapeutic none, including, but not limited to, all classifications of irritable bowel syndrome (IBS), including with a prevalence of diarrhea, with a predominance of constipation or with a changing nature of the stool, functional flatulence, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional pain abdominal syndrome, chronic idiopathic constipation, functional disorders of the esophagus, functional gastroduodenal disorders, functional anorectal pain, inflammatory disease intestinal, proliferative diseases, such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumor, a common urethral cavity cancer, a normal urethral lung cancer, a normal urethral cancer lung cancer, head and neck cancer, glioma, neuroblastoma, von Hippel-Lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, cancer gland cancer, esophageal and gastroesophageal cancer, biliary cancer and adenocarcinoma, and any malignant neoplasms with increased RET kinase activity. |
| priorityDate | 2014-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.